Raymond James Financial
VRDN icon

Raymond James Financial’s Viridian Therapeutics VRDN Stock Holding History

Raymond James Financial’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-293,308
Closed -$5.45M – 5592
2026
Q1 		$5.45M Sell
293,308
-10,466
-3% -$311K ﹤0.01% 2512
2025
Q4 		$9.42M Sell
303,774
-8,985
-3% -$246K ﹤0.01% 2012
2025
Q3 		$6.75M Sell
312,759
-19,330
-6% -$349K ﹤0.01% 2237
2025
Q2 		$4.64M Buy
332,089
+13,849
+4% +$188K ﹤0.01% 2430
2025
Q1 		$4.29M Buy
318,240
+4,453
+1% +$75.8K ﹤0.01% 2442
2024
Q4 		$6.02M Buy
+313,787
New +$6.82M ﹤0.01% 2201

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Raymond James Financial's VRDN Position: Q2 2026 in Review

Raymond James Financial sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 293,308 shares — an estimated $5.45M sold.

Raymond James Financial first reported a position in VRDN in Q4 2024 and held it in 6 quarters. The position peaked at $9.42M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Raymond James Financial reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 293,308 Viridian Therapeutics shares in Q2 2026, an estimated $5.45M.
  • Raymond James Financial first reported a position in Viridian Therapeutics in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Viridian Therapeutics position peaked at $9.42M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.